Cargando…

Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson’s Disease

Phosphorylated α-synuclein accounts for more than 90% of α-synuclein found in Lewy bodies of Parkinson’s disease (PD). We aimed to examine whether plasma Ser129-phosphorylated α-synuclein (pS129-α-synuclein) is a surrogate marker of PD progression. This prospective study enrolled 170 participants (1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chin-Hsien, Liu, Huei-Chun, Yang, Shieh-Yueh, Yang, Kai-Chien, Wu, Chau-Chung, Chiu, Ming-Jang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832465/ https://www.ncbi.nlm.nih.gov/pubmed/31623323 http://dx.doi.org/10.3390/jcm8101601

Ejemplares similares

Plasma α-synuclein predicts cognitive decline in Parkinson’s disease
por: Lin, Chin-Hsien, et al.
Publicado: (2017)

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

Plasma Biomarkers Differentiate Parkinson’s Disease From Atypical Parkinsonism Syndromes
por: Lin, Chin-Hsien, et al.
Publicado: (2018)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

Stability of Plasma Amyloid-β 1–40, Amyloid-β 1–42, and Total Tau Protein over Repeated Freeze/Thaw Cycles
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129
por: Chau, Kai-Yin, et al.
Publicado: (2013)

Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease
por: Chang, Chun-Wei, et al.
Publicado: (2020)

Development of an ultra-high sensitive immunoassay with plasma biomarker for differentiating Parkinson disease dementia from Parkinson disease using antibody functionalized magnetic nanoparticles
por: Yang, Shieh-Yueh, et al.
Publicado: (2016)

Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
por: Chiu, Pai-Yi, et al.
Publicado: (2022)

Synuclein Motor Dysfunction Composite Scale for the Discrimination of Dementia With Lewy Bodies From Alzheimer’s Disease
por: Chen, Ying-Tsung, et al.
Publicado: (2022)

Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology
por: Liu, Huei-Chun, et al.
Publicado: (2020)

Temporal trajectory of biofluid markers in Parkinson’s disease
por: Baek, Min Seok, et al.
Publicado: (2021)

Status of Current Biofluid Biomarkers in Parkinson's Disease
por: Mollenhauer, Brit
Publicado: (2023)

Synergistic Association between Plasma Aβ(1–42) and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia
por: Chiu, Ming-Jang, et al.
Publicado: (2021)

Plasma Levels of α-Synuclein, Aβ-40 and T-tau as Biomarkers to Predict Cognitive Impairment in Parkinson’s Disease
por: Chen, Nai-Ching, et al.
Publicado: (2020)

Evaluation of peripherin in biofluids of patients with motor neuron diseases
por: Sabbatini, Daniele, et al.
Publicado: (2021)

α-Synuclein serine129 phosphorylation – the physiology of pathology
por: Ramalingam, Nagendran, et al.
Publicado: (2023)

Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein
por: Bentea, Eduard, et al.
Publicado: (2015)

Membrane Binding of Parkinson's Protein α‐Synuclein: Effect of Phosphorylation at Positions 87 and 129 by the S to D Mutation Approach
por: Kumar, Pravin, et al.
Publicado: (2016)

Combining clinical and biofluid markers for early Parkinson's disease detection
por: Yu, Zhenwei, et al.
Publicado: (2017)

Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson’s disease
por: Swirski, Marta, et al.
Publicado: (2014)

Phospho-S129 Alpha-Synuclein Is Present in Human Plasma but Not in Cerebrospinal Fluid as Determined by an Ultrasensitive Immunoassay
por: Cariulo, Cristina, et al.
Publicado: (2019)

Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates
por: Arawaka, Shigeki, et al.
Publicado: (2017)

Dynamic physiological α-synuclein S129 phosphorylation is driven by neuronal activity
por: Ramalingam, Nagendran, et al.
Publicado: (2023)

Alpha-Synuclein and Parkinson’s Disease Motor and Non-Motor Symptoms: What Is New?
por: Grigoletto, Jessica, et al.
Publicado: (2022)

Biofluid Markers for Prodromal Parkinson's Disease: Evidence From a Catecholaminergic Perspective
por: Vermeiren, Yannick, et al.
Publicado: (2020)

Analytical performance of reagent for assaying tau protein in human plasma and feasibility study screening neurodegenerative diseases
por: Yang, Shieh-Yueh, et al.
Publicado: (2017)

In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129
por: Weston, Leah J., et al.
Publicado: (2021)

Assessing Plasma Levels of α-Synuclein and Neurofilament Light Chain by Different Blood Preparation Methods
por: Chang, Kuo-Hsuan, et al.
Publicado: (2021)

C-Terminal Tyrosine Residue Modifications Modulate the Protective Phosphorylation of Serine 129 of α-Synuclein in a Yeast Model of Parkinson's Disease
por: Kleinknecht, Alexandra, et al.
Publicado: (2016)

LY354740 Reduces Extracellular Glutamate Concentration, Inhibits Phosphorylation of Fyn/NMDARs, and Expression of PLK2/pS129 α-Synuclein in Mice Treated With Acute or Sub-Acute MPTP
por: Tan, Yang, et al.
Publicado: (2020)

Metabonomics: Mining for Metabolites in Biofluids
Publicado: (2002)

Extracellular vesicles in the study of Alzheimer's and Parkinson's diseases: Methodologies applied from cells to biofluids
por: Vaz, Margarida, et al.
Publicado: (2022)

Polo-like kinase 2 inhibition reduces serine-129 phosphorylation of physiological nuclear alpha-synuclein but not of the aggregated alpha-synuclein
por: Elfarrash, Sara, et al.
Publicado: (2021)

Single point mutations at the S129 residue of α-synuclein and their effect on structure, aggregation, and neurotoxicity
por: Pandit, Esha, et al.
Publicado: (2023)

Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease
por: Fan, Zheng, et al.
Publicado: (2020)

Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species
por: Ferrero, Giulio, et al.
Publicado: (2017)

Plasma Extracellular Vesicle α-Synuclein Level in Patients with Parkinson’s Disease
por: Chung, Chen-Chih, et al.
Publicado: (2021)

Modelling Ser129 Phosphorylation Inhibits Membrane Binding of Pore-Forming Alpha-Synuclein Oligomers
por: Nübling, Georg Sebastian, et al.
Publicado: (2014)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f3c0doti828vh8rvmoldqf1s8h